Hepatic venous pressure gradient measurement guiding nonselective beta‐blocker therapy in a patient with clinically significant portal hypertension
Portal hypertension & cirrhosis2023Vol. 2(2), pp. 105–108
Citations Over TimeTop 23% of 2023 papers
Abstract
Abstract Clinically significant portal hypertension (CSPH), defined as a hepatic venous pressure gradient (HVPG) ≥ 10 mmHg, is an independent risk factor for decompensated events in patients with compensated cirrhosis. Currently, the Baveno VII consensus recommends using nonselective beta‐blockers to treat compensated cirrhosis in patients with CSPH. Here, we report a unusual case of compensated cirrhosis with CSPH caused by hepatitis B, and we successfully adjust NSBBs drug treatment strategies monitoring by HVPG results and achieve response standards. Timely adjustment of NSBBs drug treatment strategies based on HVPG test results for patients with CSPH can improve the final response rate.
Related Papers
- → Approaches to the Diagnosis of Portal Hypertension: Non-Invasive or Invasive Tests?(2021)13 cited
- Are there any alternative methods to hepatic venous pressure gradient in portal hypertension assessment?(2013)
- → Cirrhosis(1991)2 cited
- Clinical analysis of 6 cases of idiopathic portal hypertension misdiagnosed as cirrhosis(2011)
- → Brief Review of Portal Hypertension Related Complications(2021)